ABCB1 c.2677G>T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD

Journal of Clinical Psychopharmacology

Volumn 33, Issue 4, 2013, Pages 491-498

  Kim, So Won ^a   Lee, Ji Hyun ^a,b   Lee, Sung Hee ^a   Hong, Hyun Ju ^c   Lee, Min Goo ^a   Yook, Ki Hwan ^d  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Hallym University   (South Korea)

^d CHA University   (South Korea)

Author keywords

ABCB1; adverse reactions; attention deficit hyperactivity disorder; genetic variation; OROS methylphenidate

Indexed keywords

ADENOSINE TRIPHOSPHATASE; METHYLPHENIDATE; MULTIDRUG RESISTANCE PROTEIN 1;

ADOLESCENT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CELL STRAIN HEK293; CHILD; CONDUCT DISORDER; DEPRESSION; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MEMBRANE VESICLE; OPPOSITIONAL DEFIANT DISORDER; OSMOTIC RELEASE ORAL SYSTEM; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TIC;

EID: 84879841085     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182905a8d     Document Type: Article

References (44)

1. Wilens TE, Biederman J, Spencer TJ. Attention deficit/hyperactivity disorder across the lifespan. Annu Rev Med. 2002;53:113-131.
2. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942-948.
3. Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit- hyperactivity disorder. N Engl J Med. 1999;340(10):780-788.
4. Nair J, Ehimare U, Beitman BD, et al. Clinical review: evidence-based diagnosis and treatment of ADHD in children. Mo Med. 2006;103(6): 617-621.
5. Reeves G, Schweitzer J. Pharmacological management of attention-deficit hyperactivity disorder. Expert Opin Pharmacother. 2004;5(6):1313-1320.
6. Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy. 2009;29(6):656-679.
7. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35(4):409-432.
8. Goldman LS, Genel M, Bezman RJ, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA. 1998;279(14):1100-1107.
9. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108(4): 883-892.
10. Steele M, Weiss M, Swanson J, et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol. 2006;13(1):e50-e62.
11. Stein MA, Sarampote CS, Waldman ID, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003;112(5):e404.
12. Barkley RA, McMurray MB, Edelbrock CS, et al. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics. 1990;86(2): 184-192.
13. Sonuga-Barke EJ, Coghill D, Wigal T, et al. Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control. J Child Adolesc Psychopharmacol. 2009;19(6):683-690.
14. McGough JJ. Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry. 2005;57(11):1367-1373.
15. Polanczyk G, Zeni C, Genro JP, et al. Attention-deficit/hyperactivity disorder: advancing on pharmacogenomics. Pharmacogenomics. 2005;6(3):225-234.
16. Froehlich TE, McGough JJ, Stein MA. Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS Drugs. 2010;24(2):99-117.
17. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem. 1997;68(5):2032-2037.
18. Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 1998;155(10):1325-1331.
19. Kieling C, Genro JP, Hutz MH, et al. A current update on ADHD pharmacogenomics. Pharmacogenomics. 2010;11(3):407-419.
20. LaHoste GJ, Swanson JM, Wigal SB, et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry. 1996;1(2):121-124.
21. Stein MA, Waldman ID, Sarampote CS, et al. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology. 2005;30(7):1374-1382.
22. Leddy JJ, Waxmonsky JG, Salis RJ, et al. Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/ hyperactivity disorder youths. J Child Adolesc Psychopharmacol. 2009;19(2):127-136.
23. Franke RM, Gardner ER, Sparreboom A. Pharmacogenetics of drug transporters. Curr Pharm Des. 2010;16(2):220-230.
24. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002;71:537-592.
25. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics. 2003;4(4):397-410.
26. Sun H, Dai H, Shaik N, et al. Drug efflux transporters in the CNS. Adv Drug Deliv Rev. 2003;55(1):83-105.
27. Zhu HJ, Wang JS, DeVane CL, et al. The role of the polymorphic efflux transporter P-glycoprotein on the brain accumulation of D-methylphenidate and D-amphetamine. Drug Metab Dispos. 2006;34(7):1116-1121.
28. Kim YS, Cheon KA, Kim BN, et al. The reliability and validity of Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime VersionVKorean version (K-SADS-PL-K). Yonsei Med J. 2004;45(1):81-89.
29. Kim YS, SY NJ, Choi NK, et al. Normative data on the Korean ADHD rating scales (K-ARS) for parents and teacher. J Korean Neuropsychiatr Assoc. 2003;42(3):352-359.
30. Wang B, Ngoi S, Wang J, et al. The promoter region of the MDR1 gene is largely invariant, but different single nucleotide polymorphism haplotypes affect MDR1 promoter activity differently in different cell lines. Mol Pharmacol. 2006;70(1):267-276.
31. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263-265.
32. Xu D, Kang H, Fisher M, et al. Strategies for inhibition of MDR1 gene expression. Mol Pharmacol. 2004;66(2):268-275.
33. Loe DW, Deeley RG, Cole SP. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 1998;58(22): 5130-5136.
34. Schinkel AH, Wagenaar E, Mol CA, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996;97(11): 2517-2524.
35. Adachi Y, Suzuki H, Sugiyama Y. Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro. Pharm Res. 2003;20(8):1163-1169.
36. Newcorn JH, Stein MA, Cooper KM. Dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder treated with OROS methylphenidate in a 4-week, open-label, dose-titration study. J Child Adolesc Psychopharmacol. 2010;20(3):187-196.
37. Karabekiroglu K, Yazgan YM, Dedeoglu C. Can we predict short-term side effects of methylphenidate immediate-release? Int J Psychiatry Clin Pract. 2008;12:48-54.
38. Ghuman JK, Riddle MA, Vitiello B, et al. Comorbidity moderates response to methylphenidate in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol. 2007;17(5):563-580.
39. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci. 2005;6(8):591-602.
40. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of pharmacotherapies for borderline personality disorder. CNS Drugs. 2008;22(8):671-692.
41. Dallas S, Miller DS, Bendayan R. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol Rev. 2006;58(2):140-161.
42. Siegmund W, Ludwig K, Giessmann T, et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther. 2002;72(5):572-583.
43. Yi SY, Hong KS, Lim HS, et al. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther. 2004;76(5):418-427.
44. Zhu HJ, Wang JS, Donovan JL, et al. Interactions of attention-deficit/ hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein. Eur J Pharmacol. 2008;578(2-3): 148-158.